Submitted by Anonymous (not verified) on 10 December 2025 - 15:18
Opinion/decision on a Paediatric investigation plan (PIP): Adtralza, tralokinumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Skin and subcutaneous tissue disorders, PIP number: P/0012/2024
Source: